Drugs / SAGE-324
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05173012 | Jan 2022 → May 2024 | essential tremor | Sage Therapeutics | Completed | Missed primary |
| Phase 2 | NCT04305275 | May 2020 → Feb 2021 | essential tremor | Sage Therapeutics | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05366751 | Jun 2022 → Sep 2024 | essential tremor | Sage Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-07-24 | Biogen | Results Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor biogen.com ↗ |
| 2021-04-12 | Biogen | Results Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint biogen.com ↗
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET). |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAGE-324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05173012 ↗ |
| Route | Oral | “Participants received SAGE-324, 60 milligrams (mg), oral tablets, once daily (QD), in the morning for 28 days.” NCT04305275 ↗ |